Skip to main content
. Author manuscript; available in PMC: 2019 Feb 16.
Published in final edited form as: ACS Chem Biol. 2018 Jan 17;13(2):455–460. doi: 10.1021/acschembio.7b00883

Figure 4.

Figure 4.

Impact of p300 bromodomain on KAT-dependent gene expression. (a) Dose-dependent inhibition of KAT-dependent gene expression by CBP30 and CBP112. (b) CBP30 does not affect dCas9-p300 overexpression. (c) Crystal structure of CBP bromodomain (PDB 2RNY) highlighting role of N1168 residue (N1132 in full length p300, N1516 in dCas9-p300) in acetyllysine recognition. (d) dCas9-p300 bromodomain mutant (N1168A) mutant is expressed at similar levels to wild-type dCas9-p300. Uncropped full blot data is provided in Supporting Information. (e) Mutations known to disrupt the p300 bromodomain-acetyllysine interaction reduce transcriptional activation by dCas9-p300. Significance analyzed by two-tailed Student’s t test (* = P < 0.05).